Glycopeptides telavancin

Telavancin Glycopeptide 2007 2008 2009 cSSSIs caused by G+ bacteria including MRSA... 

Vancomycin, a natural product that was first approved in 1955, is still the prototype for structural variations with the same mechanism of action the binding to the terminal L-Lys-D-Ala-D-Ala tripeptide in Gram-positive cell wall biosynthesis. The compounds below are semi-synthetic modifications of the same basic structural class (glycopeptides) as the prototype vancomycin, thus following in the chemical footsteps of the (1-lactams currently, there are three semi-synthetic glycopeptides, oritavancin 39, telavancin 40 and dalba-vancin 41, in late stage clinical development. 

Dalbavancin, oritavancin and telavancin are a new class of semi-synthetic glycopeptide antibiotics and are now under clinical trial. These antibiotics have important side chains and exhibit potent activity against gram-positive bacteria, including MRSA and VRE (Fig. 14, Tables 3,4). 

Telavancin is a new semisynthetic glycopeptide antibiotic with rapid bactericidal activity for gram-positive bacteria, which is mediated by a pair of biochemically distinct mechanisms inhibition of bacterial membrane phospholipids synthesis and inhibition of bacterial cell wall... 

---